Dear editor

We read with great interest the article titled “Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation” by Yan et al. We congratulate the authors for this well-organized study and would like to contribute to their findings.

The Early Treatment Diabetic Retinopathy Study demonstrated that focal laser for diabetic macular edema (DME) effectively halved the percentage of eyes that experienced vision loss and doubled the percentage of eyes that achieved visual gain. Until the past decade, focal laser photocoagulation was the standard of care for treating DME.

The development of anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment for DME. The first prospective study to compare laser monotherapy with combined laser and anti-VEGF was undertaken by the DRCRnet. Intravitreal ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA, USA) with prompt vs deferred focal/grid laser was shown to be superior to laser alone. Subsequently, the RESTORE study directly compared ranibizumab monotherapy, or in combination with focal laser, with focal laser alone. It demonstrated that ranibizumab monotherapy or the combination was superior to laser monotherapy in vision gains and in reducing central retinal thickness. Furthermore, at 1 year, no differences were detected between the ranibizumab and ranibizumab/laser arms.

Although anti-VEGF is effective for most patients, refractory DME occurs in one-quarter of eyes despite treatment. Inflammation plays a significant role in the pathophysiology of diabetes. Evidence has suggested that the release of inflammatory cytokines, including interleukin-1β and tumor necrosis factor-α, contributes to dysfunction of endothelial tight junctions, resulting in macular edema.

Consistent with these findings, steroids have been shown to be effective for treating macular edema. All steroid formulations, however, accelerate cataract formation, and they also carry the risk of increased intraocular pressure.

It is an exciting era in the treatment of DME, with effective therapies shifting our treatment paradigms. With a growing population affected by diabetes, the demand for better treatments for DME will continue to rise.

Disclosure

The author reports no conflicts of interest in this communication.
References


